US FDA extends review period for Eli Lilly and Incyte ’s rheumatoid arthritis treatment

The US Food and Drug Administration (FDA) has extended the review period for the new drug application (NDA) for Eli Lilly and Incyte ’s investigational baricitinib used to treat patients suffering from moderate-to-severe rheumatoid arthritis (RA).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news